Update on Key Emerging Challenges in Cystic Fibrosis
Mark T. Jennings(Johns Hopkins University), Michael Boyle(McMaster University), Kristin A. Riekert(Johns Hopkins University)
Cited by 3,665
Related Papers
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Multiattribute and Single-Attribute Utility Functions for the Health Utilities Index Mark 3 System
|Medical Care|2002|1.3k
Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis
|Science|1990|979
Inflammatory subtypes in asthma: Assessment and identification using induced sputum
|Respirology|2006|939
Multi-Attribute Health Status Classification Systems
|PharmacoEconomics|1995|826